HRTX
Heron Therapeutics
$0.46
+$0.00 (+0.66%)Jul 27, 2026
Key metrics
The numbers that frame HRTX today
- Market cap
- $86.88M
- P/E (TTM)
- -2.8
- EV / FCF
- -9.7
- Gross margin
- 71.1%
- EV / Sales
- 1.3
- ROIC
- -10%
- Div yield
- 0%
- Debt / equity
- 15.5
- 52wk Low
- $0.38
- 52wk High
- $1.93
Growth
Revenue and earnings trend for HRTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about HRTX
Is Heron Therapeutics a good buy?
No. Heron Therapeutics has weak quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Heron Therapeutics is selling at a high price.
What is the market capitalization of HRTX?
Heron Therapeutics's market capitalization is $86.88M.
What is the P/E ratio for HRTX stock?
Heron Therapeutics's current P/E ratio is -2.8.
What is the 52-week high for HRTX stock?
The 52-week high for Heron Therapeutics is $1.93. The current close of $0.46 is 76.2% below that high.
What is the 52-week low for HRTX stock?
The 52-week low for Heron Therapeutics is $0.38. The current close of $0.46 is 20.2% above that low.
Does HRTX stock pay dividends?
Heron Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for HRTX?
Heron Therapeutics's Debt / Equity ratio is 15.5.